Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]OXD-2314
- Development stage
- Unknown
- Lead developer
- Center for Addiction and Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]OXD-2314 is a first-in-class, pan-tau positron emission tomography (PET) radiopharmaceutical designed for the in vivo imaging of tau aggregates across Alzheimer's disease and non-Alzheimer's disease (non-AD) tauopathies. Developed through a ligand-based design approach using a fluoropyridinyl-indole scaffold, [18F]OXD-2314 exhibits high affinity and selectivity for 3R, 4R, and mixed 3R/4R tau fibrils. It demonstrates minimal off-target binding to other neurodegenerative disease targets such as amyloid-beta, alpha-synuclein, or monoamine oxidases (MAO-A and MAO-B). The tracer is currently being evaluated in early-phase clinical trials to detect tau pathology in living patients with suspected chronic traumatic encephalopathy (CTE) and progressive supranuclear palsy (PSP).
- Other names
- 18F-OXD-23142-(2-fluoro-6-(3-methoxypiperidin-1-yl)pyridin-3-yl)-1H-indol-5-olfluorine-18 OXD-2314fluorine18 OXD-2314fluorine 18 OXD-2314
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on [18F]OXD-2314.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]OXD-2314.